MIAMI

Monitoring innate immunity in arthritis and mucosal inflammation

 Coordinatore WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER 

 Organization address address: SCHLOSSPLATZ 2
city: MUENSTER
postcode: 48149

contact info
Titolo: Ms.
Nome: Julija
Cognome: Winschel
Email: send email
Telefono: +49 251 8354036

 Nazionalità Coordinatore Germany [DE]
 Sito del progetto http://www.miamiproject.eu/
 Totale costo 7˙453˙018 €
 EC contributo 5˙703˙145 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2012-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-02-01   -   2016-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

 Organization address address: SCHLOSSPLATZ 2
city: MUENSTER
postcode: 48149

contact info
Titolo: Ms.
Nome: Julija
Cognome: Winschel
Email: send email
Telefono: +49 251 8354036

DE (MUENSTER) coordinator 1˙252˙400.00
2    BUHLMANN LABORATORIES AG

 Organization address address: BASELSTRASSE 55
city: SCHONENBUCH
postcode: 4124

contact info
Titolo: Mr.
Nome: Oliver
Cognome: Grether
Email: send email
Telefono: +41 61 487 1219
Fax: +41 61 487 1234

CH (SCHONENBUCH) participant 1˙118˙044.00
3    UNIVERSITEIT GENT

 Organization address address: SINT PIETERSNIEUWSTRAAT 25
city: GENT
postcode: 9000

contact info
Titolo: Mrs.
Nome: Nathalie
Cognome: Vandepitte
Email: send email
Telefono: +32 9 264 30 29

BE (GENT) participant 824˙770.00
4    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

 Organization address address: BELFIELD
city: DUBLIN
postcode: 4

contact info
Titolo: Mr.
Nome: Donal
Cognome: Doolan
Email: send email
Telefono: +353 1 716 1497

IE (DUBLIN) participant 774˙039.00
5    UNIVERSITAIR MEDISCH CENTRUM UTRECHT

 Organization address address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX

contact info
Titolo: Dr.
Nome: Anne-Marie
Cognome: Laeven-De Boer
Email: send email
Telefono: +31 88 7554250
Fax: +31 88 7555351

NL (UTRECHT) participant 640˙940.00
6    STICHTING KATHOLIEKE UNIVERSITEIT

 Organization address address: GEERT GROOTEPLEIN NOORD 9
city: NIJMEGEN
postcode: 6525 EZ

contact info
Titolo: Dr.
Nome: Peter
Cognome: Van Lent
Email: send email
Telefono: +31 24 3610512
Fax: +31 24 3540403

NL (NIJMEGEN) participant 581˙348.00
7    Biogazelle

 Organization address address: Kruishoutemstraat 57
city: Zulte
postcode: 9870

contact info
Titolo: Dr.
Nome: Barbara
Cognome: D'haene
Email: send email
Telefono: +32 9 241 5608
Fax: +32 9 241 5656

BE (Zulte) participant 392˙604.00
8    EUROPEAN RESEARCH SERVICES GMBH

 Organization address address: ROENTGENSTRASSE 19
city: MUENSTER
postcode: 48149

contact info
Titolo: Mr.
Nome: Oliver
Cognome: Panzer
Email: send email
Telefono: +49 251 8330340

DE (MUENSTER) participant 119˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

damage    deleterious    biomarkers    alleviate    mechanisms    seronegative    family    problem    diagnosis       identification    pattern    therapeutic    joint    disease    translate    personalised    arthritis    autoimmunity    gut    release    disability    immunity    inflammation    miami    therapies    initiation    immune    significant    molecular    protect    inflammatory    chronic    correlate    proteins    activation    monitoring    course    innate    autoimmune    progression    mucosal    patients    prediction   

 Obiettivo del progetto (Objective)

'In chronic joint disease, only a subgroup of patients has classical autoantibodies, while the other variants are seronegative arthritis syndromes with a predominance of innate immune disturbances. These forms of joint diseases frequently show extra-articular manifestations of epithelial tissues like skin and gut. On the molecular level, innate immune activation and the release of damage associated molecular pattern proteins (DAMPs) of the S100 family are important mechanisms of initiation and perpetuation. Early diagnosis remains a significant problem, and prediction of disease extension and course is challenging. Despite all efforts we do not have therapies that alleviate the disease and protect from disease progression, damage and long-term disability. The identification of specific inflammatory mechanisms that correlate to patterns of disease characteristics would allow targeted therapeutic approaches. In a comprehensive research approach, MIAMI will establish relevant disease mechanisms and translate finding into novel biomarkers for individual adaptation of therapies (personalised medicine) for seronegative arthritis. Our research strategy leaves retracted ways of genetics and classical autoimmunity; instead we will focus on innate immunity and inflammation. The goals of MIAMI are ambitious and will be reached with cutting-edge research performed by the most excellent researchers in the field, who have been combined to form a multidisciplinary consortium. The choice of the scientific as well as industry partners was entirely based on excellence. Thus, MIAMI brings together the leading teams that are working on mechanisms of innate immunity in arthritis and mucosal inflammation. In summary, MIAMI will significantly contribute to progress on the key questions: Who will be affected by which disease manifestation or complication, how can we use this knowledge to identify the disease, and what will be a meaningful target to treat or even prevent deleterious outcome.'

Introduzione (Teaser)

Early diagnosis of joint arthritis remains a significant problem, and prediction of disease progression and course is challenging. The identification of disease biomarkers should help in this respect.

Descrizione progetto (Article)

Chronic inflammatory disorders of the joints are not necessarily associated with autoimmunity. Emerging evidence clearly shows that a number of patients with inflammatory arthritis suffer from disturbed innate immune responses and have no presence of autoimmune antibodies.

Currently, there are no therapies that alleviate the disease and protect from disease progression, damage and long-term disability. As a result, it is important to delineate the specific mechanisms that correlate with inflammatory disease in order to design more effective and targeted therapeutic approaches.

The scope of the EU-funded 'Monitoring innate immunity in arthritis and mucosal inflammation' (http://www.miamiproject.eu/ (MIAMI)) project is to consolidate existing biomarkers and develop novel ones for personalised therapy in non-autoimmune arthritis. Preliminary study results indicate that innate immune activation is associated with the release of damage-associated molecular pattern proteins of the S100 family. In both patients and experimental models, these molecules seem important for disease initiation and progression.

Key project activities also include the development of novel methodologies for efficient and early diagnosis of chronic joint and gut inflammation. MIAMI partners will associate S100 proteins with disease stage and identify which of these could serve as biomarkers for populations at risk and those with progressive disease. Following extensive cytokine, transcriptomic and proteomic analyses, scientists hope to identify novel biomarkers as well for monitoring local inflammation and disease progression.

With the help of participating small and medium-sized enterprises, MIAMI hopes to translate these findings into clinically validated assays. Coupled with biomarker identification, the activities of the MIAMI study should identify new disease targets for treating or even preventing deleterious outcomes.

Altri progetti dello stesso programma (FP7-HEALTH)

MATIND (2011)

Large scale innovative pro-poor programs focused on reducing maternal mortality in India: a proposal for impact evaluation

Read More  

EU-HPSCREG (2013)

European human Pluripotent Stem Cell Registry

Read More  

MEDCHAMPS (2009)

MEDiterranean studies of Cardiovascular disease and Hyperglycaemia: Analytical Modelling of Population Socio-economic transitions

Read More